Medical Equipment

Liver Cancer Diagnostics Market Size and Growth Forecast for Businesses 2025–2029

November 17, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Liver Cancer Diagnostics Market Size During 2025–2029?

The market encompassing diagnostics for liver cancer has experienced substantial expansion recently, with projections indicating a rise from $9.69 billion in 2024 to $10.32 billion the following year, reflecting a compounded annual growth rate of 6.5%; this upward trend throughout the historical period stems from advancements in areas such as biopsy methodologies and histopathology, the creation of novel biomarker detection methods, progress in population screening initiatives, enhancements in genetic analysis, and superior liver imaging technologies.

Projected to experience considerable expansion shortly, the market for liver cancer diagnostics is anticipated to reach a valuation of $13.71 billion by 2029, achieving a compound annual growth rate (CAGR) of 7.4% throughout this period, with this upward trajectory being fueled by factors such as evolving regulatory landscapes and greater uniformity, the increasing significance placed on various imaging techniques, progress in next-generation sequencing capabilities, broader implementation of screening initiatives accompanied by heightened public consciousness, and the escalating need for diagnostic testing rooted in biomarkers.Key shifts characterizing this forecast timeframe involve an increase in both the occurrence and widespread nature of the disease, technological leaps forward within the imaging sector, a greater emphasis being placed on diagnostic methods that do not involve invasive procedures, the move towards highly specific and individually tailored diagnostic approaches, and the incorporation of artificial intelligence (AI) technologies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10481&type=smp

What Are The Top Growth Drivers Impacting The Liver Cancer Diagnostics Market Outlook?

Anticipated increases in the occurrence rates of liver cancer are projected to fuel the expansion of the market dedicated to diagnosing this disease. This serious ailment, characterized by the uncontrolled proliferation of liver cells, necessitates diagnostic procedures designed to ascertain the extent to which cancerous cells have infiltrated the liver or adjacent tissues following an initial diagnosis of primary liver carcinoma; consequently, the escalating incidence directly stimulates the market for liver cancer diagnostics. Illustratively, data from the American Cancer Society’s Cancer Facts & Figures 2023 report, released in January 2023 by the US-based non-profit health group, depicted an uptick in new cases of liver and intrahepatic bile duct cancer among females in the United States, moving from 12,640 recorded in 2020 to 13,230 in 2023. Moreover, projections for 2023 indicate that an estimated 41,210 new instances of liver cancer will be identified in the US, with an expected mortality of 29,380 individuals; this growing burden of liver cancer prevalence is therefore the primary force pushing forward the liver cancer diagnostic market.

What Are The Emerging Segments Gaining Attention In The Liver Cancer Diagnostics Market?

The liver cancer diagnosticsmarket covered in this report is segmented –

1) By Type: Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Other Types

2) By Screening: Laboratory Testing, Imaging, Endoscopy, Biopsy, Other Screenings

3) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies

4) By End Use: Hospitals And Diagnostic Laboratories, Academic And Research Institutes, Pharmaceutical And CRO Laboratories

Subsegments:

1) By Hepatocellular Carcinoma: Early-Stage Hepatocellular Carcinoma, Advanced-Stage Hepatocellular Carcinoma

2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma

3) By Hepatoblastoma: Pure Hepatoblastoma, Mixed Hepatoblastoma

4) Other Types: Secondary Liver Cancer, Fibrolamellar Carcinoma

What Are The Major Trends Driving The Growth Of The Liver Cancer Diagnostics Market?

Leading firms within the liver cancer diagnostic landscape are busy creating sophisticated testing methods reliant on biomarkers and intricate computational models to boost the precision of diagnoses and facilitate earlier identification. These biomarker-driven assays and related algorithms represent diagnostic instruments leveraging distinct biological indicators for disease identification, thereby offering heightened accuracy and more streamlined identification processes. Illustratively, in November of 2023, the US biotechnology entity Roche Diagnostics introduced both the Elecsys PIVKA-II assay and the Elecsys GAAD algorithm. The Elecsys PIVKA-II specifically targets elevated concentrations of the PIVKA-II marker, which is correlated with hepatocellular carcinoma (HCC), consequently refining the prompt detection of liver malignancy among individuals facing elevated risk. Furthermore, the Elecsys GAAD algorithm synthesizes several diagnostic markers, including AFP alongside PIVKA-II, with the goal of sharpening diagnostic exactitude and simplifying the decision-making pathways in diagnosing liver cancer.

Who Are The Prominent Global Companies Shaping The Liver Cancer Diagnostics Market?

Major companies operating in the liver cancer diagnostics market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen NV, Thermo Fisher Scientific Inc., Siemens Healthineers, Illumina Inc., Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc., Danaher Corporation, Foundation Medicine Inc., Agilent Technologies Inc., Genemed Biotechnologies Inc., Merck KGaA, Fujifilm Medical Systems USA Inc., GE Healthcare, Advanced Cell Diagnostics Inc., Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon A/S, BioGenex Laboratories Inc., OncoCyte Corporation, Guardant Health Inc., Exact Sciences Corporation, Grail Inc., Freenome Holdings Inc., Natera Inc., Personal Genome Diagnostics Inc., Thrive Earlier Detection Corp

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report

Which Region Currently Holds The Largest Share Of The Liver Cancer Diagnostics Market?

North America was the largest region in the liver cancer diagnostics market in 2024. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Liver Cancer Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=10481&type=smp

Browse Through More Reports Similar to the Global Liver Cancer Diagnostics Market 2025, By The Business Research Company

Molecular Diagnostics Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-devices-and-equipment-global-market-report

Point Of Care Diagnostics Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-devices-and-equipment-global-market-report

Molecular Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795